Pharmacy groups on warpath over AMP

Paul, Reid
July 2007
Drug Topics;7/23/2007, Vol. 151 Issue 14, p10
Trade Publication
The article reports that the U.S. Centers for Medicare & Medicaid Services' (CMS) release of the final version of its average manufacturer price (AMP) rule has received universal disapproval from pharmacy organizations. The rule implements one of the elements of the Deficit Reduction Act of 2005, mandating CMS to begin to calculate federal upper limits for generic drug reimbursement in the Medicaid program based on AMP data. Comments from National Association of Chain Drug Stores president and chief executive officer (CEO) Steven C. Anderson and the American Pharmacists Association are presented.


Related Articles

  • States divided over Medicaid AMP rule. Paul, Reid // Drug Topics;6/4/2007, Vol. 151 Issue 11, p24 

    The article reports that several U.S. states have already started to take action to prevent the impact of Centers for Medicare and Medicaid Services' final rule for implementation of average manufacturer price (AMP) for Medicaid reimbursement on generic drugs which is expected to take effect on...

  • Judge rules against AMP.  // Drug Topics;1/14/2008, Vol. 152 Issue 1, p6 

    The article reports that Judge Royce Lamberth has granted a temporary injunction which stops the Centers for Medicare & Medicaid Services (CMS) from implementing the average manufacturer price (AMP) rule for Medicaid generic drug reimbursement in the U.S. The move was taken in response to the...

  • Medicaid Muddle. Toth, Wendy; Alaimo, Dan // SN: Supermarket News;8/13/2007, Vol. 55 Issue 33, p25 

    The article focuses on the Medicaid generic drug reimbursement formula released by the U.S. Centers for Medicare & Medicaid Services. The payment method will use the Average Manufacturer Price of drugs to establish a reimbursement formula. The old calculation used the Average Wholesaler Price....

  • CMS drops AMP Christmas surprise.  // Drug Topics;1/8/2007, Vol. 151 Issue 1, p8 

    The article examines the new rules issued by the Centers for Medicare and Medicaid Services (CMS)regarding the Medicaid reimbursement in the U.S. Issued on December 22, 2006, the new rules aims to cut more that $8 billion in Medicaid prescription generic drugs over a five year period. CMS hopes...

  • Industry looks to Congress, states for Mediôaid relief.  // Drug Store News;8/13/2007, Vol. 29 Issue 10, p56 

    The article reports that the pharmaceutical industry has turned for relief to Congress after failing to stop the new Medicaid payment guidelines for generic drugs by the Centers for Medicare & Medicaid Services (CMS) in the U.S. Pharmacy leaders raised concerns over the impact of the rules on...

  • BRACING FOR A SHOWDOWN. Paul, Reid // Drug Topics;2/11/2008, Vol. 152 Issue 3, p30 

    The article reports on the criticisms of pharmacy organizations concerning the U.S. Centers for Medicare and Medicaid Services's (CMS) proposed average manufacturer price (AMP) rule. According to the author, the National Community Pharmacists Association (NCPA) has predicted that the AMP rule...

  • Proposed Part D rule changes could be bane to brand drugmakers. Serebrov, Mari // BioWorld Today;1/8/2014, Vol. 25 Issue 5, p1 

    The article discusses the U.S. Centers for Medicare & Medicaid Services' proposal of Part D rule change that would tip the formulary scale in favor of generics and biosimilars which is seen as a bane to pharmaceutical firms. The changes aims to remove the protection antidepressants and...

  • Pharmacists livid and desperate over AMP rule. Paul, Reid // Drug Topics;8/6/2007, Vol. 151 Issue 15, p18 

    The article reports on the implementation of the average manufacturer price (AMP) reimbursement rule for Medicaid generic drugs by the Centers for Medicare & Medicaid Services (CMS). The rule states that drug prices in the Medicaid program will be reimbursed at two hundred fifty percent of the...

  • Medicaid reimbursement. Baker, Kenneth R. // Drug Topics;Jul2012, Vol. 156 Issue 7, p16 

    The article presents information on how the new rules, proposed by the U.S. Centers for Medicare and Medicaid Services (CMS) for covered outpatient drugs, will affect pharmacies and the patients. The new rules are expected to change the amount of reimbursement and professional fees, received by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics